Surya Patra

ALL
News
Opinion
Photos
Videos

Jump to

PhillipCapital's Surya Patra on Sun Pharmaceutical

In an interview to CNBC-TV18, Surya Patra of PhillipCapital shared his readings and outlook on the pharmaceutical space.
Positive on IPCA, but see 4% impact on earnings: Phillip Capital

Surya Patra, pharma analyst at Phillip Capital now estimates IPCA's institutional revenues to fall to around Rs 200 crore, from its earlier estimate of around Rs 260 crore

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Surya Patra

PhillipCapital's Surya Patra on Sun Pharmaceutical

Positive on IPCA, but see 4% impact on earnings: Phillip Capital